Next 10 |
2023-05-10 07:25:24 ET PolyPid press release ( NASDAQ: PYPD ): Q1 GAAP EPS of $0.28 beats by $0.56 . As of March 31, 2023, the Company had cash and cash equivalents and deposits in the amount of $13.4 million, Research and development (R&D) expenses f...
Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site Infections ; Recruitment Expected to Re sume Imminently Received Advice from the Swedish Medical Prod...
PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2023 financial results...
2023-04-14 16:27:35 ET PolyPid ( NASDAQ: PYPD ) said it had received a letter from the listing firm Nasdaq stating it was no longer in compliance with the minimum equity requirement for continued listing The Company has 45 days, or until May 25, to submit a plan to regain comp...
PETACH TIKVA, Israel, April 14, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received a letter from the Listing Qualifications sta...
Company Also Restructures Existing Kreos Loan, Deferring Over $3 Million of Repayment PETACH TIKVA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve...
2023-03-29 08:31:40 ET PolyPid ( NASDAQ: PYPD ) shares fell 18% premarket on Wednesday after the biopharma company priced its securities offering to raise around $6.2M in gross proceeds. The offering comprises 14.66M ordinary shares, issued at $0.42 each. The under...
PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the pricing of an underwritten public offering of 14,660,000...
2023-03-28 16:25:18 ET PolyPid ( NASDAQ: PYPD ) said Tuesday it commenced an underwritten public offering of its ordinary shares. In addition, PolyPid intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of ordinary shares. ...
PETACH TIKVA, Israel, March 28, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that it has commenced an underwritten public offering of its...
News, Short Squeeze, Breakout and More Instantly...
PolyPid Ltd. Company Name:
PYPD Stock Symbol:
NASDAQ Market:
PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma compa...
PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD), ("PolyPid" or the "Company"), a late-stage biopharma compa...
PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma compan...